The majority of patients dying from their malignant disease (metastatic disease at the time of diagnosis, later death from relapse) were included in a cluster characterized by especially higher levels of IL6, IL33Rα, and TNFα compared to the other main cluster, whereas IL1RA and CRP only showed differences with borderline significance. This evidence concerns the gene IL6 and metastatic neoplasm.